GMAB.DK

1,717

-0.09%↓

COLO.B.DK

403.9

-2.53%↓

HLUNB.DK

41.9

+0.19%↑

ZEAL.DK

316.7

+0.44%↑

AMBUB.DK

68.15

+1.34%↑

GMAB.DK

1,717

-0.09%↓

COLO.B.DK

403.9

-2.53%↓

HLUNB.DK

41.9

+0.19%↑

ZEAL.DK

316.7

+0.44%↑

AMBUB.DK

68.15

+1.34%↑

GMAB.DK

1,717

-0.09%↓

COLO.B.DK

403.9

-2.53%↓

HLUNB.DK

41.9

+0.19%↑

ZEAL.DK

316.7

+0.44%↑

AMBUB.DK

68.15

+1.34%↑

GMAB.DK

1,717

-0.09%↓

COLO.B.DK

403.9

-2.53%↓

HLUNB.DK

41.9

+0.19%↑

ZEAL.DK

316.7

+0.44%↑

AMBUB.DK

68.15

+1.34%↑

GMAB.DK

1,717

-0.09%↓

COLO.B.DK

403.9

-2.53%↓

HLUNB.DK

41.9

+0.19%↑

ZEAL.DK

316.7

+0.44%↑

AMBUB.DK

68.15

+1.34%↑

Kodu・Aktsiate loetelu・Novo Nordisk A-S (Class B)

Novo Nordisk A-S (Class B)

Suletud

288.45 1.26

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

286.85

Max

289.85

Põhinäitajad
By Trading Economics
Sissetulek	22B 49B
Müük	18B 97B
P/E Sektori keskmine	10.403 49.701
Aktsiakasum	10.91
Dividenditootlus	4.09
Kasumimarginaal	50.15
Töötajad	67,900
EBITDA	32B 69B

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+9.53% upside

Dividendid
By Dow Jones
Dividenditootlus Sektori keskmine	4.09% 2.39%
Järgmine tulemuste avaldamine	5. aug 2026
Järgmine aktsia dividendi kuupäev (ex-date)	13. aug 2026

Turustatistika
By TradingEconomics
Turukapital	8.6B 1.3T
Eelmine avamishind	287.19
Eelmine sulgemishind	288.45

Novo Nordisk A-S (Class B) Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

11. mai 2026, 15:48 UTC

Omandamised, ülevõtmised, äriostud

Novo Nordisk to Sell Parkinson's Cell Therapy to Startup Cellular Intelligence

6. mai 2026, 07:30 UTC

Tulu

Wegovy Maker Novo Nordisk Lifts Guidance Following Strong Launch of Weight-Loss Pill -- Update

6. mai 2026, 06:19 UTC

Tulu

Wegovy Maker Novo Nordisk Lifts Guidance Following Strong Launch of Weight-Loss Pill

18. mai 2026, 13:10 UTC

Market Talk

Tulu

Novo Nordisk Report Shows Bright Spots Amid Price Pressure -- Market Talk

12. mai 2026, 12:05 UTC

Kuumad aktsiad

Stocks to Watch: GameStop, Venture Global, Wendy's, Hims & Hers -- WSJ

12. mai 2026, 10:51 UTC

Kuumad aktsiad

Stocks to Watch: GameStop, Venture Global, Hims & Hers, GoPro -- WSJ

12. mai 2026, 09:42 UTC

Tulu

Hims & Hers Stock Sinks. Why Earnings Offered Wall Street a Big Surprise. -- Barrons.com

12. mai 2026, 09:08 UTC

Kuumad aktsiad

Stocks to Watch: Venture Global, Hims & Hers, GoPro -- WSJ

11. mai 2026, 20:30 UTC

Tulu

Hims & Hers Stock Sinks. Why Earnings Offered Wall Street a Big Surprise. -- Barrons.com

7. mai 2026, 09:30 UTC

Tulu

America's Weight-Loss Drug Boom Is Going Global -- Heard on the Street -- WSJ

6. mai 2026, 12:36 UTC

Tulu

Novo's Weight-Loss Pill Heaps Pressure on Eli Lilly. Stock Jumps After Earnings. -- Barrons.com

6. mai 2026, 10:53 UTC

Kuumad aktsiad

Stocks to Watch Today: Advanced Micro Devices, Samsung, Disney -- WSJ

6. mai 2026, 10:12 UTC

Tulu

Novo Stock Rises After Earnings. It's Taking the Weight-Loss Drug Fight to Eli Lilly. -- Barrons.com

6. mai 2026, 09:58 UTC

Tulu

Novo Nordisk Shares Jump on Strong Demand for Wegovy Pill -- 2nd Update

6. mai 2026, 09:35 UTC

Kuumad aktsiad

Stocks to Watch Today: Advanced Micro Devices, Samsung, Disney -- WSJ

6. mai 2026, 08:13 UTC

Market Talk

Tulu

Novo Nordisk Guidance Tweak Unlikely to Drive Upgrades -- Market Talk

6. mai 2026, 07:43 UTC

Market Talk

Tulu

Novo Nordisk Consensus Earnings Expectations Likely to Rise -- Market Talk

6. mai 2026, 07:00 UTC

Tulu

Novo Nordisk Shares Rise 5.5% After 1Q Results

6. mai 2026, 06:34 UTC

Tulu

Novo Nordisk Execs Were Speaking on Media Call After 1Q Earnings

6. mai 2026, 06:26 UTC

Tulu

Novo Nordisk CFO: Branded GLP-1 Market is Expanding

6. mai 2026, 06:26 UTC

Tulu

Novo Nordisk CFO: Data Indicates There is a Lower Share of Compounders in The Market

6. mai 2026, 06:24 UTC

Tulu

Novo Nordisk CFO: Believe We've Found a Sweet Spot in Terms of Pricing With Wegovy Pill

6. mai 2026, 06:20 UTC

Tulu

Novo Nordisk CEO: Very Excited By What We See With Wegovy Pill

6. mai 2026, 06:19 UTC

Tulu

Novo Nordisk CFO: So Far Competitor's Pill Hasn't Impacted Wegovy Pill Trajectory

6. mai 2026, 06:13 UTC

Tulu

Novo Nordisk CEO: Continue To Try and Improve Our Pipeline Internally and Externally

6. mai 2026, 06:13 UTC

Tulu

Novo Nordisk CEO: Seen Continued Interest In Our Pill Despite Competitor Entering Market

6. mai 2026, 06:12 UTC

Tulu

Novo Nordisk CFO: Impact From Higher Oil Prices is Immaterial to Co

6. mai 2026, 05:43 UTC

Tulu

Novo Nordisk: Total Wegovy Pill Prescriptions Since Launch Now Exceed 2M

6. mai 2026, 05:42 UTC

Tulu

Novo Nordisk: Total Prescriptions For Wegovy Pill in 1Q Reached Around 1.3M

6. mai 2026, 05:40 UTC

Tulu

Novo Nordisk: First Wegovy Pill Launches Outside U.S. Expected During 2H26

Võrdlus sarnastega

Hinnamuutus

Novo Nordisk A-S (Class B) Prognoos

Hinnasiht

By TipRanks

9.53% tõus

12 kuu keskmine prognoos

Keskmine 1,162.73 DKK 9.53%

Kõrge 1,550 DKK

Madal 720 DKK

Põhineb 11 Wall Streeti analüütiku instrumendi Novo Nordisk A-S (Class B) 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

11 ratings

Osta

Hoia

Müü

Põhineb 11 analüütiku instrumendi Novo Nordisk A-S (Class B) aktsia reitingul - viimase 3 kuu andmed.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Novo Nordisk A-S (Class B)

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.